pateclizumab   Click here for help

GtoPdb Ligand ID: 9854

Synonyms: MLTA3698A | PRO283698 | RG7416
Immunopharmacology Ligand
Compound class: Antibody
Comment: Pateclizumab is a humanized anti-lymphotoxin alpha (LTA) monoclonal antibody that is being investigated for anti-inflammatory potential. Peptide sequences for the heavy and light chains of pateclizumab are 100% matches to sequences 106 and 107 that are claimed in Genentech's patent US7923011B2 [1]. Sequences 106 and 107 identify pateclizumab as antibody 2C8.vX as defined in the patent.
No information available.
Summary of Clinical Use Click here for help
Pateclizumab (as research code MLTA3698A) has completed Phase 2 clinical trial in patients with active rheumatoid arthritis. In this trial (NCT01225393) MLTA3698A plus a DMARD was directly compared with adalimumab plus a DMARD, and results were reported by Kennedy et al. (2014) [4].
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The role of LTA in RA is reviewed by Hirose et al. (2018) [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01225393 A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis Phase 2 Interventional Genentech, Inc.